Protocol for a within-trial economic evaluation of a psychoeducational intervention tailored to people at high risk of developing a second or subsequent melanoma. Issue 10 (6th October 2016)

• Record Type: Journal Article
• Authors: Dieng, M; Cust, A E; Kasparian, N A; Butow, P; Costa, D S J; Menzies, S W; Mann, G J; Morton, R L
• Is Part Of: BMJ open. Volume 6:Issue 10(2016)
• Publication Date: 2016-10-06
• Subjects: Cost-effectiveness analysis -- cost-utility analysis -- QALY -- cancer -- Fear of cancer recurrence -- Psychological intervention; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2016-012153
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Psychological support programmes are not currently funded for people with a history of melanoma. A major barrier to the implementation of effective psychological interventions in routine clinical care is a lack of cost-effectiveness data. This paper describes the planned economic evaluation alongside a randomised controlled trial of a psychoeducational intervention for people with a history of melanoma who are at high risk of developing new primary disease. Method and analysis: The economic evaluation is a within-trial analysis to evaluate the incremental costs and health outcomes of a psychoeducational intervention compared to usual care from the perspective of the Australian healthcare system. Cost-effectiveness and cost-utility analyses will be conducted, providing estimates of the cost to reduce fear of melanoma recurrence and the cost per quality-adjusted life-year (QALY) gained. Fear of melanoma recurrence will be measured using the Fear of Cancer Recurrence Inventory and preference-based quality of life measured using the Assessment of Quality of Life—8 Dimensions (AQoL-8D) instrument. The AQoL-8D will provide utilities for estimation of QALYs in the cost-utility analysis. Unit costs of health services and medicines will be taken from the Medicare Benefits Schedule and the Pharmaceutical Benefits Scheme national databases. Health outcomes, and health service and medication use will be collected at baseline, 6 and 12 months follow-up. The within-trial analysis will be conducted at 12 months, consistent with the end point of the trial. Ethics and dissemination: Approval to conduct the study was granted by the Sydney Local Health District (RPAH zone) Ethics Review Committee (X13-0065 and HREC/13/RPAH/86), the Department of Health and Ageing Human Research Ethics Committee (21/2013), the University of Sydney Human Research Ethics Committee (2013/595), and the Australian Institute of Health and Welfare Ethics Committee (EO 2013/4/58). Trial registration number: ACTRN12613000304730; Pre-results.